Evonik and Transferra Nanosciences, Inc., formerly known as Northern Lipids Inc., a Canadian contract development and manufacturing organization signed an asset purchase agreement on June 21st, 2016 under which Evonik will acquire the business and assets of Transferra Nanosciences Inc.The transaction is scheduled to close at the end of July 2016.

Transferra specializes in liposomal drug-delivery systems. The acquisition allows Evonik to further expand in the area of parenteral drug-delivery technologies and services. Transferra services include prototype identification, scale-up and process development, analytical support and qualification of methods, production of test articles for toxicology studies and cGMP manufacturing of clinical trial materials. In addition, Transferra offers a range of benchtop Lipex extruders, as well as custom-built Lipex extruders for large-scale manufacture of commercial drug products.

Source: Evonik